Finn
MDGL Biotechnology · Commercial biotech · NASH · Single product · Thesis updated November 8, 2026

First profit achieved, but massive trial costs loom for 2027

01 Running thesis

A U.S. blockbuster facing 2027 margin pressure

Madrigal continues to see massive demand for Rezdiffra in the U.S. market. In Q3 2026, the company crossed 55,850 active patients and reported $431.3 million in net sales. This volume growth pushed Rezdiffra past $1 billion in year-to-date sales and delivered the company's first quarter of profitability.

The company is aggressively expanding its target market. Madrigal increased its addressable patient estimate for the F4c cirrhosis market to 360,000 patients. To capture this group, the company will initiate a massive new 2,000-patient Phase 3 trial called MAESTRO-CSPH in early 2027.

The bear case now focuses on heavy costs and pricing headwinds expected next year. Initiating the MAESTRO-CSPH trial and three Phase 2 combination studies will require a massive spike in research and development spending. Management warned that profitability may dip in and out as these costs hit the income statement.

Adding to the pressure, gross-to-net discounts will step up to the high end of the 30 percent range in 2027 as Medicare Part D contracts activate. Investors must weigh the flawless commercial execution against a tightening margin profile and delayed European expansion.

Nov 2026▲Q3 2026 net sales reached $431.3M, delivering the company's first quarter of profitability. Management announced a massive new Phase 3 trial for 2027, but warned that Medicare Part D will increase pricing discounts next year.
Jul 2026▲Q2 2026 net sales reached $364.3M as active patients surpassed 50,000. New patents strengthened the intellectual property moat, but management warned that European revenue will be negligible this year due to reimbursement hurdles.
May 2026→Q1 2026 showed both sides of the story. Rezdiffra net sales reached $311.3M, up 127 percent year over year, but the net loss widened to $94.4M as SG&A and R&D spending jumped.
Feb 2026→Full-year 2025 Rezdiffra sales reached $958M, proving the launch was strong. The view stayed balanced because heavy SG&A and R&D spending pushed the profit timeline out.
Aug 2025▲Q2 2025 sales rose 55 percent quarter over quarter to $213M, and patient growth kept building. A new U.S. patent extending protection to February 2045 made the long-term Rezdiffra franchise more valuable.
May 2025▲Q1 2025 net revenue of $137.3M beat expectations and rose 33 percent from Q4 2024. Treated patients passed 17,000, which strengthened confidence in the launch.
Feb 2025▲Q4 2024 net sales reached $103M, up 66 percent quarter over quarter. Patients on Rezdiffra rose to more than 11,800, and the F4 cirrhosis opportunity became a bigger part of the upside case.
02 Business model

Selling through liver specialists

Madrigal makes money entirely from Rezdiffra. The company sells the drug in the U.S. through a limited specialty pharmacy network. The main prescribers are hepatologists, gastroenterologists, and an expanding group of endocrinologists.

Because this is a first-in-disease launch, Madrigal bears the full cost of market education. It must teach doctors how to find the right patients, help offices process prescriptions, and secure payer coverage. This creates a strong early lead but requires significant upfront investment.

The moat relies on patent protection. Madrigal holds U.S. patents extending exclusivity to 2045, covering the commercial weight-based dosing regimen. New patents also protect the drug in the F2 and F3 disease stages, which complicates potential future generic entry.

While all current revenue comes from the U.S., Madrigal is trying to open the European market. However, strict price controls and Most Favored Nation pricing rules make those negotiations very difficult.

03 Product portfolio

One drug, many follow-ons

Growth engine

Rezdiffra

The only commercial product and total revenue base today. It is approved for noncirrhotic NASH with moderate to advanced liver fibrosis.

Option

F4 cirrhosis expansion

Supported by the MAESTRO-NASH OUTCOMES trial reading out in late 2027 and the new MAESTRO-CSPH trial starting in early 2027.

Option

MGL-2086

An oral GLP-1 program meant to support combination treatments. A Phase 2 combination trial is expected to start in 2027.

Option

Ervogastat

A DGAT2 inhibitor brought in to build combination therapy options, with Phase 2 trials planned for 2027.

Option

MGL-0795

An siRNA therapeutic recently in-licensed. This adds another mechanism to the pipeline, also slated for 2027 Phase 2 trials.

04 Business segments

U.S. sales and European delays

U.S. Rezdiffra100%growing fast
Europe direct launch0%flat

For Q3 2026, Madrigal reported $431.3 million of product revenue. The internal segment view treats all material current revenue as U.S. Rezdiffra sales. Europe is modeled as a zero-revenue segment this year due to reimbursement challenges.

05 Risk factors

What could break the thesis

Margin pressure from Medicare

High impact · High odds

Gross-to-net discounts are expected to increase in 2027 to the high end of the 30 percent range as Medicare Part D contracts activate. This will pressure unit economics just as the company accelerates research spending.

We watchQuarterly gross-to-net discount percentages.

Return to cash burn

High impact · Medium odds

Madrigal achieved profitability in Q3 2026, but the massive new MAESTRO-CSPH trial and three Phase 2 combination trials require heavy spending next year. This research burden could push the company back into meaningful losses.

We watchQuarterly R&D expenses and net income margins.

European reimbursement failures

High impact · High odds

Management expects negligible European revenue this year because of tough pricing negotiations. If Madrigal cannot secure favorable reimbursement abroad, the total addressable market shrinks.

We watchEuropean revenue contribution and pricing agreement updates.

Future drug competition

High impact · Medium odds

NASH is a massive market, and other companies are developing treatments, including GLP-1 drugs. While Madrigal has a lead, better data from a competitor could erode its dominance.

We watchCompetitor trial readouts and FDA actions.
06 Quick answers

In one breath

What does Madrigal Pharmaceuticals do?

Madrigal sells Rezdiffra, a drug for certain NASH patients with moderate to advanced liver scarring. It also builds a pipeline of follow-on treatments in the same disease area.

Why is Rezdiffra important?

Rezdiffra was the first approved drug for its target NASH population. That gives Madrigal a massive early lead with doctors, payers, and specialty pharmacies.

Is Madrigal profitable?

The company reported its first profitable quarter in Q3 2026. However, heavy research spending on new clinical trials starting in 2027 could push the company back into temporary losses.

What is the next big catalyst for MDGL?

The next year centers on the initiation of the large MAESTRO-CSPH trial in early 2027, monitoring Medicare pricing impacts, and the expected late 2027 readout for the F4 cirrhosis outcomes trial.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Madrigal Pharmaceuticals Q3 2026 Earnings Transcript
  2. Madrigal Pharmaceuticals Q2 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near Madrigal Pharmaceuticals, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today